Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

NCT03392389 | Completed Phase 1 DMC FDA Drug

• 1 other identifier: mRNA-1653-P101
• Study Type: interventional
• Target: 124
• Locations: 1 country
• Sites: 3

Brief Summary

This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.

Conditions

Human Metapneumovirus and Human Parainfluenza Infection

Keywords

mRNA-1653; human metapneumovirus; human parainfluenza vaccine

Outcome Measures

Primary Outcomes (7)

• Frequency of solicited AEs (local and systemic reactogenicity events)

  7 days following each dose administration

• Frequency of unsolicited adverse events

  28 days following each dose administration

• Frequency of serious adverse events (SAE), adverse events of special interest (AESI), and medically-attended AEs

  one year following the last dose administration

• Frequency of clinical laboratory adverse events

  1 month following the last dose administration

• Geometric mean titer (GMT) of the serum anti-hMPV and anti-PIV3 neutralizing antibodies

  1 month following the last dose administration

• Proportion of subjects with a ≥ 4-fold increase in serum anti-hMPV and anti-PIV3 neutralizing antibody titer from baseline to post-vaccination

  1 month following the last dose administration

• Proportion of subjects who achieve serum anti-hMPV and anti-PIV3 neutralizing antibody titers greater than the third quartile of the serum anti-hMPV and anti-PIV3 antibody titers overall distribution at baseline

  1 month following the last dose administration

Secondary Outcomes (3)

• Geometric mean titer (GMT) of the serum anti-hMPV and anti-PIV3 neutralizing antibodies

  6 months and 1 year following the last dose administration

• Proportion of subjects with a ≥ 4-fold increase in serum anti-hMPV and anti-PIV3 neutralizing antibody titer from baseline to post-vaccination

  6 months and 1 year following the last dose administration

• Proportion of subjects who achieve serum anti-hMPV and anti-PIV3 neutralizing antibody titers greater than the third quartile of the serum anti-hMPV and anti-PIV3 antibody titers overall distribution at baseline

  6 months and 1 year following the last dose administration

Study Arms (2)

mRNA-1653

EXPERIMENTAL

Biological: mRNA-1653

Placebo

PLACEBO COMPARATOR

Other: Placebo

Interventions

mRNA-1653 BIOLOGICAL

Escalating dose levels

mRNA-1653

Placebo OTHER

Saline

Placebo

Eligibility Criteria

• Age: 18 Years - 49 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Agrees to comply with the study procedures and provides written informed consent
• to 49 years of age
• Body mass index between 18 and 35 kg/m2
• In good health based on medical history, physical examination, vital sign measurements and laboratory safety tests performed prior to initial study vaccination
• Negative urine pregnancy test at the screening visit and the day of each vaccination for females of childbearing potential
• Female subjects must either be of non-childbearing potential or use acceptable methods of contraception from at least 30 days prior to enrollment and through 3 months following last vaccination
• Willing to comply with the requirements of the protocol (eg, complete Diary Cards, return for follow-up visits, be available for safety phone calls)

You may not qualify if:

• Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care
• A history of malignancy in the last 10 years
• If female and of childbearing potential, is pregnant or lactating, has not adhered to an adequate contraception method from at least 30 days before study entry, or does not plan to do so for at least 3 months after the last vaccination
• Abnormal screening safety laboratory test results including liver enzyme tests
• Administration of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine or has plans for administration during the study period
• Prior administration of investigational agent using lipid nanoparticle formulations
• A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies
• A positive test result for drugs of abuse
• Chronic administration of potentially hepatotoxic drugs or have other medical conditions that affect the liver (eg, alcohol abuse)
• A history of idiopathic urticaria
• Plans for administration or has been administered a vaccine within the period from 30 days before through 30 days after each study vaccination, with the exception of any licensed influenza vaccine administered ≥15 days before or after any study vaccination
• Any chronic administration of an immunosuppressant or other immune modifying drug
• Prior administration of immunoglobulins and/or any blood products within the 3 months before the first study vaccine or has plans for administration during the study period
• Any known or suspected immune-mediated disease or immunosuppressive condition as determined by medical history and/or physical examination
• A history of hypersensitivity or serious reactions to previous vaccinations

Sponsors & Collaborators

• ModernaTX, Inc.: lead

Study Sites (3)

Meridian Clinical Research, LLC

Omaha, Nebraska, 68134, United States

Location

Benchmark Research

Austin, Texas, 78705, United States

Location

Benchmark Research

Fort Worth, Texas, 76135, United States

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 2, 2018
• First Posted: January 8, 2018
• Study Start: December 4, 2017
• Primary Completion: July 29, 2019
• Study Completion: July 29, 2019
• Last Updated: February 6, 2020

Record last verified: 2020-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)